Alessandra Graziottin
Research Subjects
Alessandra Graziottin has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Cynthia A. Rodenberg
Procter and Gamble Pharmaceuticals Inc. , Mason, OH , USA
1 shared publicationLaura Bertolasi
1 shared publicationLori A. Brotto
University of Washington , Seattle, Washington, USA
1 shared publicationLorraine Dennerstein
Office for Gender and Health, Department of Psychiatry, The University of Melbourne , Melbourne , Australia
1 shared publicationMara Bottanelli
1 shared publicationNiccolò Giovannini
1 shared publication
Latest Publications
- 1 August 2009
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 6 (8) , 2143-2153
The Prevalence of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women: An Epidemiological Study of Women in Four European Countries
Introduction: Insufficient documentation exists regarding the prevalence of hypoactive sexual desire disorder (HSDD) in surgically menopausal (SM) women in European countries. Women who have undergone hysterectomy and bilateral oophorectomy experience a loss of ovarian hormones. Inclusion of these women in an epidemiological study provided the opportunity to study biological and cultural impacts on sexual function. Aim: The aim of this study was to compare the prevalence of HSDD among SM women in France, Germany, Italy, and the United Kingdom, as well as the relationship between low sexual desire and sexual activity or behavior, and sexual or partner relationship satisfaction. Methods: Cross-sectional survey of a convenience sample of 427 SM women aged 20–70 years. Main Outcome Measures: The desire domain of the Profile of Female Sexual Function (PFSF) to identify women with low sexual desire, Personal Distress Scale (PDS) to measure distress caused by low sexual desire, and a sexual activities measure. Women with low sexual desire who were distressed were classified as having HSDD. Results: SM women having low sexual desire ranged from 35% (United Kingdom) to 44% (Italy); of these women, 16% (Germany) to 56% (France) were distressed because of their low sexual desire. Overall, SM women classified with HSDD ranged from 7% (Germany) to 22% (France). A strong positive correlation was observed between sexual desire and arousal, orgasm, and sexual pleasure in all countries (P < 0.001). Low sexual desire leads to less sexual activity, more dissatisfaction with sex life and partner relationship, and more negative emotional or psychological states, than normal desire in each country. Conclusions: A similar percentage of SM women with low sexual desire were found across countries suggesting the role of biological factors (i.e., losing ovarian hormones) in determining sexual desire. Differences in the percentage of SM women with HSDD suggest a role for cultural factors in determining how low sexual desire is perceived.
- 1 August 2009
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 6 (8) , 2143-2153
The Prevalence of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women: An Epidemiological Study of Women in Four European Countries
Introduction: Insufficient documentation exists regarding the prevalence of hypoactive sexual desire disorder (HSDD) in surgically menopausal (SM) women in European countries. Women who have undergone hysterectomy and bilateral oophorectomy experience a loss of ovarian hormones. Inclusion of these women in an epidemiological study provided the opportunity to study biological and cultural impacts on sexual function. Aim: The aim of this study was to compare the prevalence of HSDD among SM women in France, Germany, Italy, and the United Kingdom, as well as the relationship between low sexual desire and sexual activity or behavior, and sexual or partner relationship satisfaction. Methods: Cross-sectional survey of a convenience sample of 427 SM women aged 20–70 years. Main Outcome Measures: The desire domain of the Profile of Female Sexual Function (PFSF) to identify women with low sexual desire, Personal Distress Scale (PDS) to measure distress caused by low sexual desire, and a sexual activities measure. Women with low sexual desire who were distressed were classified as having HSDD. Results: SM women having low sexual desire ranged from 35% (United Kingdom) to 44% (Italy); of these women, 16% (Germany) to 56% (France) were distressed because of their low sexual desire. Overall, SM women classified with HSDD ranged from 7% (Germany) to 22% (France). A strong positive correlation was observed between sexual desire and arousal, orgasm, and sexual pleasure in all countries (P < 0.001). Low sexual desire leads to less sexual activity, more dissatisfaction with sex life and partner relationship, and more negative emotional or psychological states, than normal desire in each country. Conclusions: A similar percentage of SM women with low sexual desire were found across countries suggesting the role of biological factors (i.e., losing ovarian hormones) in determining sexual desire. Differences in the percentage of SM women with HSDD suggest a role for cultural factors in determining how low sexual desire is perceived.
- Open Access
- 1 July 2007
- Published by SAGE Publications in Women's Health
- Vol. 3 (4) , 455-474
Effect of Premature Menopause on Sexuality
Premature menopause, that is, menopause – spontaneous or iatrogenic – occurring at or before the age of 40 years, affects sexual identity, sexual function and sexual relationships. The woman's health, wellbeing and achievement of life's goals may be variably impaired. Factors modulating the individual's sexual outcome after premature menopause include: etiological heterogeneity of premature menopause and associated medical and sexual comorbidities; psychosexual vulnerability to premature menopause and associated infertility in survivors of childhood and adolescent cancers; impact of premature menopause on women's sexual identity, sexual function – particularly the biological basis of desire, arousal, orgasm and vaginal receptivity – and sexual relationships; partner-related factors; fertility issues; and preventive/therapeutic measures. Hormone therapy is indicated but long-term safety data are lacking. An interdisciplinary medical and psychosexual approach comprises appropriate counseling, fertility protection, when feasible, individualized hormone therapy and specific psychosexual treatment(s). Further research on fertility protection and the safety of long-term hormone therapy after premature menopause is needed.
- 1 July 2007
- Published by SAGE Publications in Women's Health
- Vol. 3 (4) , 455-474
Open AccessEffect of Premature Menopause on Sexuality
Premature menopause, that is, menopause – spontaneous or iatrogenic – occurring at or before the age of 40 years, affects sexual identity, sexual function and sexual relationships. The woman's health, wellbeing and achievement of life's goals may be variably impaired. Factors modulating the individual's sexual outcome after premature menopause include: etiological heterogeneity of premature menopause and associated medical and sexual comorbidities; psychosexual vulnerability to premature menopause and associated infertility in survivors of childhood and adolescent cancers; impact of premature menopause on women's sexual identity, sexual function – particularly the biological basis of desire, arousal, orgasm and vaginal receptivity – and sexual relationships; partner-related factors; fertility issues; and preventive/therapeutic measures. Hormone therapy is indicated but long-term safety data are lacking. An interdisciplinary medical and psychosexual approach comprises appropriate counseling, fertility protection, when feasible, individualized hormone therapy and specific psychosexual treatment(s). Further research on fertility protection and the safety of long-term hormone therapy after premature menopause is needed.
- 1 September 2005
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 2 (Supplement) , 133-145
Biological and Psychosocial Pathophysiology of Female Sexual Dysfunction During the Menopausal Transition
Introduction: Although increasing age is a primary determinant of reduced sexual function in older women, hormonal changes may be significant contributors to female (and couples’) sexual dysfunction.Aim: To analyze the most relevant biological, psychosexual, and/or contextual factors that influence changes in women's sexuality during and after menopause.Methods: A Postmenopausal FSD Roundtable consisting of multidicsiplinary international experts was convened to review specific issues related to postmenopausal women and sexual dysfunction.Main Outcome Measure: Expert opinion was based on a review of evidence-based medical literature, presentation, and internal discussion.Results: Menopause is associated with physiological and psychological changes that influence sexuality: the primary biological change is a decrease in circulating estrogen levels. Estrogen deficiency initially accounts for irregular menstruation and diminished vaginal lubrication. Continual estrogen loss is associated with changes in the vascular, muscular, and urogenital systems, and also alterations in mood, sleep, and cognitive functioning, influencing sexual function both directly and indirectly. The age-dependent decline in testosterone and androgen function, starting in the early 20s, may precipitate or exacerbate aspects of female sexual dysfunction; these effects are most pronounced following bilateral ovariectomy and consequent loss of 50% or more total testosterone. The contribution of progestogens to sexual health and variability in the effects of specific progestogens are being increasingly appreciated. Comorbidities, influenced by loss of sexual hormones, between mood and desire disorders and urogenital and sexual pain disorders are common and remain frequently overlooked in clinical practice. Physical and psychosexual changes may contribute to lower self-esteem, and diminished sexual responsiveness and sexual desire. Nonhormonal factors that affect sexuality are health status and current medication use, changes in or dissatisfaction with partner, partner's health and/or sexual problems, and socioeconomic status.Conclusion: Determination of the best way to provide optimal management of sexual dysfunction associated with menopause requires additional controlled studies.
- 1 September 2005
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 2 (Supplement) , 133-145
Biological and Psychosocial Pathophysiology of Female Sexual Dysfunction During the Menopausal Transition
Introduction: Although increasing age is a primary determinant of reduced sexual function in older women, hormonal changes may be significant contributors to female (and couples’) sexual dysfunction.Aim: To analyze the most relevant biological, psychosexual, and/or contextual factors that influence changes in women's sexuality during and after menopause.Methods: A Postmenopausal FSD Roundtable consisting of multidicsiplinary international experts was convened to review specific issues related to postmenopausal women and sexual dysfunction.Main Outcome Measure: Expert opinion was based on a review of evidence-based medical literature, presentation, and internal discussion.Results: Menopause is associated with physiological and psychological changes that influence sexuality: the primary biological change is a decrease in circulating estrogen levels. Estrogen deficiency initially accounts for irregular menstruation and diminished vaginal lubrication. Continual estrogen loss is associated with changes in the vascular, muscular, and urogenital systems, and also alterations in mood, sleep, and cognitive functioning, influencing sexual function both directly and indirectly. The age-dependent decline in testosterone and androgen function, starting in the early 20s, may precipitate or exacerbate aspects of female sexual dysfunction; these effects are most pronounced following bilateral ovariectomy and consequent loss of 50% or more total testosterone. The contribution of progestogens to sexual health and variability in the effects of specific progestogens are being increasingly appreciated. Comorbidities, influenced by loss of sexual hormones, between mood and desire disorders and urogenital and sexual pain disorders are common and remain frequently overlooked in clinical practice. Physical and psychosexual changes may contribute to lower self-esteem, and diminished sexual responsiveness and sexual desire. Nonhormonal factors that affect sexuality are health status and current medication use, changes in or dissatisfaction with partner, partner's health and/or sexual problems, and socioeconomic status.Conclusion: Determination of the best way to provide optimal management of sexual dysfunction associated with menopause requires additional controlled studies.
- 1 December 2004
- Published by Springer Nature in Current Sexual Health Reports
- Vol. 1 (4) , 151-156
Vulvar vestibulitis: Pathophysiology and management
- 1 December 2004
- Published by Springer Nature in Current Sexual Health Reports
- Vol. 1 (4) , 151-156
Vulvar vestibulitis: Pathophysiology and management
- 1 November 2004
- Published by Wolters Kluwer Health in Menopause
- Vol. 11 (6) , 766-777
Sexual dysfunction in women with premature menopause
To discuss assessment and management of sexual dysfunctions associated with premature menopause. Literature review plus clinical observations. Studies on assessment and management of sexual dysfunctions associated with premature menopause are minimal. Premature menopause affects sexual identity, sexual function, and sexual relationship. Major modulating factors include etiology, life cycle stage, factors personal to the woman, and family and societal influences. Loss of ovarian function in adolescence may delay psychosexual maturity via psychological and biological mechanisms. Maternity becomes impossible, unless ovodonation is feasible, accepted, and legally available. Loss of sexual desire, subjective and genital arousal, and orgasm may be highly distressing. Reduction of sex hormones and psychological reactions of both partners to the prematurity and infertility are etiologically important. Estrogen therapy is usually indicated, but long-term safety data in this population are lacking. Testosterone therapy, also lacking in safety data and mainly investigational, may be needed to restore sexual arousability. Presence, age, and sexual health of the partner, having children, and quality of intimacy in previous and present relationships modulate coping attitudes and clinical outcome. An interdisciplinary medical and psychosexual approach comprises individualized hormone therapy and specific psychosexual treatment(s). Research into optimal management of sexual dysfunction with premature menopause is urgently needed.
- 1 November 2004
- Published by Wolters Kluwer Health in Menopause
- Vol. 11 (6) , 766-777
Sexual dysfunction in women with premature menopause
To discuss assessment and management of sexual dysfunctions associated with premature menopause. Literature review plus clinical observations. Studies on assessment and management of sexual dysfunctions associated with premature menopause are minimal. Premature menopause affects sexual identity, sexual function, and sexual relationship. Major modulating factors include etiology, life cycle stage, factors personal to the woman, and family and societal influences. Loss of ovarian function in adolescence may delay psychosexual maturity via psychological and biological mechanisms. Maternity becomes impossible, unless ovodonation is feasible, accepted, and legally available. Loss of sexual desire, subjective and genital arousal, and orgasm may be highly distressing. Reduction of sex hormones and psychological reactions of both partners to the prematurity and infertility are etiologically important. Estrogen therapy is usually indicated, but long-term safety data in this population are lacking. Testosterone therapy, also lacking in safety data and mainly investigational, may be needed to restore sexual arousability. Presence, age, and sexual health of the partner, having children, and quality of intimacy in previous and present relationships modulate coping attitudes and clinical outcome. An interdisciplinary medical and psychosexual approach comprises individualized hormone therapy and specific psychosexual treatment(s). Research into optimal management of sexual dysfunction with premature menopause is urgently needed.
- 1 May 2004
- Published by Taylor & Francis in Journal of Sex & Marital Therapy
- Vol. 30 (3) , 125-139
Vulvar Vestibulitis Syndrome: A Clinical Approach
Vulvar vestibulitis syndrome (VVS) is a heterogeneous, multisystemic, and multifactorial disease and is one of the leading causes of dyspareunia in fertile women. As a multisystemic disease, it involves the mucous structure of the vulvar vestibule and the immune, muscular, vascular, and nervous systems, including pain fibers and centers. As a multifactorial disease, its etiology is complex, involving biological, psychosexual, and relational factors. In this article, we discuss the progression of the disease and the impact of an often lengthy delay between the onset of symptoms and a correct diagnosis. Moreover, despite documented improvements from available treatments, VVS becomes a chronic disease unless it is diagnosed early and an integrated, pathophysiologically oriented treatment is offered in an experienced center. Health care providers would therefore benefit from approaching the condition within a pain management framework focused on the woman's chronic pain, the impact on the couple's relationship, and any associated psychological sequelae.
- 1 May 2004
- Published by Taylor & Francis in Journal of Sex & Marital Therapy
- Vol. 30 (3) , 125-139
Vulvar Vestibulitis Syndrome: A Clinical Approach
Vulvar vestibulitis syndrome (VVS) is a heterogeneous, multisystemic, and multifactorial disease and is one of the leading causes of dyspareunia in fertile women. As a multisystemic disease, it involves the mucous structure of the vulvar vestibule and the immune, muscular, vascular, and nervous systems, including pain fibers and centers. As a multifactorial disease, its etiology is complex, involving biological, psychosexual, and relational factors. In this article, we discuss the progression of the disease and the impact of an often lengthy delay between the onset of symptoms and a correct diagnosis. Moreover, despite documented improvements from available treatments, VVS becomes a chronic disease unless it is diagnosed early and an integrated, pathophysiologically oriented treatment is offered in an experienced center. Health care providers would therefore benefit from approaching the condition within a pain management framework focused on the woman's chronic pain, the impact on the couple's relationship, and any associated psychological sequelae.
- 1 October 2001
- Published by Taylor & Francis in Journal of Sex & Marital Therapy
- Vol. 27 (5) , 489-501
Clinical Approach to Dyspareunia
Dyspareunia needs to be addressed from an integrated patient-centered perspective. This review analyzes the organic causes of pain during intercourse. Factors that are often underevaluated in the clinical setting include hormonal, inflammatory, muscular, iatrogenic, neurologic, vascular, connective, and immunitary causes. Psychosexual factors, such as vaginismus, loss of libido, arousal disorders and sexual pain-related disorders, often overlap. A preliminary clinical approach aimed at integrating different biological and psychosexual etiologies in a comprehensive manner is discussed in this article.
- 1 October 2001
- Published by Taylor & Francis in Journal of Sex & Marital Therapy
- Vol. 27 (5) , 489-501
Clinical Approach to Dyspareunia
Dyspareunia needs to be addressed from an integrated patient-centered perspective. This review analyzes the organic causes of pain during intercourse. Factors that are often underevaluated in the clinical setting include hormonal, inflammatory, muscular, iatrogenic, neurologic, vascular, connective, and immunitary causes. Psychosexual factors, such as vaginismus, loss of libido, arousal disorders and sexual pain-related disorders, often overlap. A preliminary clinical approach aimed at integrating different biological and psychosexual etiologies in a comprehensive manner is discussed in this article.